Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Revenue (2021)

Atea Pharmaceuticals has reported Revenue over the past 1 years, most recently at $192.2 million for Q4 2021.

  • Quarterly results put Revenue at $192.2 million for Q4 2021, changed N/A from a year ago — trailing twelve months through Sep 2022 was $192.2 million (up 20.73% YoY), and the annual figure for FY2021 was $351.4 million, up 622.49%.
  • Revenue for Q4 2021 was $192.2 million at Atea Pharmaceuticals, up from $32.8 million in the prior quarter.
  • Over the last five years, Revenue for AVIR hit a ceiling of $192.2 million in Q4 2021 and a floor of $32.8 million in Q3 2021.